Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Calidi Biotherapeutics, Inc./ S-3MEF

SEC Filing · S-3MEF

Calidi Biotherapeutics, Inc.

CLDINYSE_AMERICANEQUITYCurrent

SEC Filing

Filed Mar 5, 2026Accepted Mar 5, 2026, 9:59 PM ESTCIK 1855485Accession 0001493152-26-009037
View company →Permanent SEC source ↗
Share

Company context

We are a clinical stage biotechnology company developing genetic medicines and proprietary genetically-engineered oncolytic viruses. We are currently developing RedTail, an enveloped vaccinia virus platform designed to deliver genetic medicine to tumor sites, and two proprietary stem cell-based oncolytic virus platforms (SuperNova and NeuroNova). The RedTail platform is expected to open an IND by the end of 2026 with the first compound (CLD-401) delivering IL-15 superagonist to the tumor microenvironment (“TME”).

Current securities

CLDINYSE_AMERICAN · EQUITY · CurrentCLDWWOTC · WARRANT · Current
Historical securities (4)
CLDI.WSNYSE_AMERICAN · WARRANT · Historical · closed Oct 18, 2024FLAGNYSE · ETF · Historical · closed Sep 13, 2023FLAG.UNNYSE · UNIT · Historical · closed Sep 12, 2023FLAG.WSNYSE_AMERICAN · WARRANT · Historical · closed Sep 12, 2023

Recent company filings

  1. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other EventsSep 25, 2026
  2. Entry into a Material Definitive Agreement · Other EventsSep 22, 2026
  3. 424B5 filingSep 17, 2026
  4. 4 filingAug 19, 2026
  5. 4 filingAug 19, 2026

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.